+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
UCB (Union chimique belge) - logo

UCB is a global biopharmaceutical company that focuses on neurology and immunology. The company’s core products are Cimzia, Vimpat, Neupro, Keppra and Briviact, and they are also preparing the launch of a potential medicine to help patients with osteoporosis. It offers products for the treatment of central nervous system disorders, allergy and respiratory diseases, and immune and inflammatory disorders. UCB employs over 7,000 people and is based in Brussels, Belgium.

cFMS Kinase Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

cFMS Kinase Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Asthma Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Asthma Therapeutics - Global Strategic Business Report

  • Report
  • October 2025
  • 194 Pages
  • Global
From
Craniopharyngioma Treatment - Global Strategic Business Report - Product Thumbnail Image

Craniopharyngioma Treatment - Global Strategic Business Report

  • Report
  • October 2025
  • 401 Pages
  • Global
From
From
Transdermal Drug Delivery Market 2025-2029 - Product Thumbnail Image

Transdermal Drug Delivery Market 2025-2029

  • Report
  • August 2025
  • 228 Pages
  • Global
From
From
Dermatological Drugs Market Report 2024-2034 - Product Thumbnail Image

Dermatological Drugs Market Report 2024-2034

  • Report
  • February 2024
  • 280 Pages
  • Global
From
From
Loading Indicator